Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
Yi Xia(The University of Texas MD Anderson Cancer Center), Ken H. Young(Duke Medical Center), Jane N. Winter(Northwestern University), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), J Li(Beijing University of Chinese Medicine), Laura Pasqualucci(Columbia University Irving Medical Center), Govind Bhagat(Columbia University Irving Medical Center), Benjamin M. Parsons(Gundersen Health System), Maurilio Ponzoni(San Raffaele University of Rome), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Eric D. Hsi(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Zijun Y. Xu‐Monette(Duke University), Attilio Orazi(Texas Tech University), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Shaozeng Zhang(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), Y Li(Cleveland Clinic Lerner College of Medicine), Chi Young Ok(The University of Texas MD Anderson Cancer Center), Kristy L. Richards(University of North Carolina at Chapel Hill), April Chiu(Mayo Clinic), Xiqi Li(Baylor College of Medicine), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Youli Zu(Methodist Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Jooryung Huh(Asan Medical Center), L. Jeffrey Medeiros(Delaware Division of Libraries), William W.L. Choi(Chinese University of Hong Kong), Vundavalli V. Murty(Cancer Genetics (United States))
Cited by 64
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k